A lip lift is surgery that shortens the skin above the lip. Lip filler is an injection that adds volume inside the lip. They fix different problems, and no trial has ever compared them.
The lip lift treats a proportion problem. A subnasal or "bullhorn" lip lift removes a strip of skin immediately under the base of the nose, shortening the cutaneous upper lip — the philtrum. That rotates the pink part of the lip outward and upward, so more of it shows and more of the upper teeth show at rest. It adds no volume at all.
Lip filler treats a volume problem. A hyaluronic acid gel is injected into the lip itself. It makes a thin lip fuller and more projected. It does not shorten the distance between the nose and the lip — and at higher volumes in a long upper lip it pushes the pink forward while the philtrum stays long, which is why a heavily filled long lip can read as unnatural.
The genuine asymmetry is permanence. A lip lift leaves a scar at the base of the nose. It is usually well hidden in the natural crease, but it is permanent, and the operation cannot be undone. Hyaluronic acid filler can be broken down with hyaluronidase, and it fades on its own over months to years even if nothing is done.
The evidence sits differently for each, and that is not the same as one being better. Lip fillers are regulated products approved through randomised, evaluator-blinded trials. A lip lift is a surgical procedure, so it never went through product approval at all — its evidence is four observational studies with no randomised trial among them, but with follow-up running out to nearly five years.
The pink of the lip rotates outward and upward. No volume is added.
The lip becomes fuller and more projected. The philtrum is unchanged.
That comes from four observational studies. Nothing longer has been measured.
Juvederm Ultra XC's lip trial: 79.1% of treated people met a one-grade improvement at month 3, 56.4% at month 12. Restylane Kysse: 60% at week 48. Restylane Silk: 58.8% at week 24. Separate products, separate scales, not comparable with each other.
Surgery leaves a permanent scar at the base of the nose, and over-shortening of the philtrum cannot be reversed.
Hyaluronidase breaks down hyaluronic acid filler. It is an off-label use in the US, there is no standardised dose, and repeat dosing is normal.
Usually well camouflaged, visible in some people. Scar widening or thickening is described in the surgical literature. There is no published incidence figure for any of it.
Skin dying from a blocked blood vessel can scar, and that is the serious risk rather than the routine outcome.
A systematic review screened 464 articles and found four eligible: two retrospective cohorts and two case series. 92.4% female, ages 21 to 65, mean 36.6. All showed improvement on measurement and on patient satisfaction, stable over the follow-up.
Lip augmentation is a named FDA-approved indication for Juvederm Ultra XC, Juvederm Volbella XC, Restylane, Restylane-L, Restylane Silk, Restylane Kysse, Revanesse Lips+, RHA 3 and RHA 3 Mepi, and Belotero Intense (+) Lidocaine.
Described complications include scar widening, over-shortening producing a permanently toothy look, distortion of the nostril base, asymmetry, temporary numbness and infection. No systematic review has tabulated how often these happen, so no percentages should be quoted.
The serious risk is filler entering an artery, which can cause skin death and, rarely, blindness. Cheek and lip were the two most frequently named injection sites in reports to the FDA's adverse event database — a count of reports with no denominator, so it cannot be turned into a chance for any individual.
The distinction is between distance and volume. If the space between the base of your nose and the pink of your lip has got longer, and no upper teeth show when your face is at rest, that is a proportion problem and filler does not address it. Adding gel pushes the vermilion forward without shortening anything; at higher volumes it can flatten the philtral columns and make the lip look longer still.
If the philtrum is a normal length and the lip itself is simply thin, that is a volume problem, and it is the one filler is approved to treat.
You will find specific numbers circulating for this — a philtral length above roughly 15 mm in women, a certain millimetre range of tooth show at rest. Those thresholds are widely repeated in clinic copy but have not been verified against a primary source, so no figure appears on this page. An in-person assessment of the actual measurements on your face is the only way to answer it.
The best synthesis is a 2022 systematic review of the subnasal lip lift. Its authors searched five databases, screened 464 articles and found four that qualified — two retrospective cohorts and two case series, with no randomised controlled trials. The pooled population was 92.4% female, aged 21 to 65 with a mean of 36.6 years, and a bullhorn excision pattern was used in 75% of the studies. Every study reported aesthetic improvement on anthropometric measurement and on patient satisfaction, and results were stable over follow-up of 12 to 59.1 months. The authors concluded that the procedure improves lip aesthetics and maintains stability "for a certain period of time."
Two things that review does not give you: the millimetres of philtral shortening or tooth-show gain, and any tabulation of how often complications occur. Those figures were not in the published record, so any page quoting a scar rate or a revision rate for lip lift is quoting something unsourced.
What is solid is the structural point. A lip lift is surgery, it produces a permanent scar at the base of the nose, and it cannot be reversed. Over-shortening the philtrum produces a permanently toothy appearance that cannot be corrected by adding the skin back.
Each approved lip product has its own randomised, evaluator-blinded trial, its own scale and its own numbers, and they do not transfer between products.
Juvederm Ultra XC's lip indication was approved in September 2015 on a trial of 213 people randomised 3:1 against a delayed-treatment control. 79.1% of treated people met a one-grade improvement on the lip fullness scale at month 3, against 26.1% of controls. At month 12 it was 56.4% — meaning about 44% of treated people no longer met even a one-grade improvement at the last measured timepoint.
Restylane Kysse's trial ran 48 weeks, with 88% of people meeting a one-grade improvement at week 8 and 60% at week 48. It was a non-inferiority design against an unnamed comparator, so it demonstrates nothing about being better than anything else.
Two things to hold on to. A "responder" here is anyone with a one-grade improvement on a four- or five-point manufacturer-developed scale, which is a low bar. And a duration figure is the end of the study's follow-up window, not a lifespan.
After filler:
Any change in vision, blurred vision or vision loss in one or both eyes
Sudden severe pain, or pain out of proportion to the procedure
Skin turning white or pale, then dusky, mottled or net-patterned
Weakness, drooping, slurred speech or any other stroke-like symptom
These suggest filler has entered or blocked an artery, and time matters in hours. Published guidance treats a suspected blockage of an artery to the eye as a same-hour emergency. Do not use pain as your gauge — in a survey of experienced injectors, pain was mild or absent in 47% of the intravascular injections reported.
After surgery, go to an emergency department for heavy bleeding that will not stop, a spreading fever, or rapidly increasing swelling and pain around the wound.
Swelling is still increasing after the first few days rather than settling
A lump forms and does not settle, or appears weeks or months later
Redness spreads outward from the treated area
Tenderness or firmness appears late, particularly after an illness, a vaccination or dental work
Filler looks like it has moved outside the lip border
A surgical wound opens, the scar starts thickening or widening, or numbness under the nose is not improving